Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis

We evaluated treatment patterns and healthcare costs of initiating psoriatic arthritis (PsA) treatment with oral apremilast versus biologics. Claims data identified biologic-naive adults with PsA who initiated either apremilast or a biologic from 2013 to 2016. Medication adherence was similar at 12...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2019-07, Vol.8 (9), p.699-709
Main Authors: Feldman, Steven R, Pelletier, Corey L, Wilson, Kathleen L, Mehta, Rina K, Brouillette, Matthew A, Smith, David, Bonafede, Machaon M
Format: Article
Language:English
Subjects:
adherence
Arthritis
Consumer-driven health plans
Economic impact
Health care expenditures
Health care policy
Health maintenance organizations
HMOs
Laboratories
Patients
persistence
Pharmacy
phosphodiesterase 4 inhibitor
Population
Psoriasis
Psoriatic arthritis
Rheumatism
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated treatment patterns and healthcare costs of initiating psoriatic arthritis (PsA) treatment with oral apremilast versus biologics. Claims data identified biologic-naive adults with PsA who initiated either apremilast or a biologic from 2013 to 2016. Medication adherence was similar at 12 months (76.9 vs 73.4%; p = 0.175) between apremilast (n = 381) and matched biologic (n = 761) patients. Apremilast users had $12,715 lower total costs per-patient-per-month (p < 0.001), largely due to outpatient pharmacy and medical costs. Commercially insured patients with PsA initiating apremilast had adherence similar to those initiating biologics but lower total healthcare costs.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2019-0034